CompletedPhase 1NCT02031198

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Axon Neuroscience SE
Principal Investigator
Reinhold Schmidt, Professor
Medizinische Universität Graz
Intervention
AADvac1(drug)
Enrollment
25 enrolled
Eligibility
50-86 years · All sexes
Timeline
20142016

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02031198 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease

← Back to all trials